Zymeworks INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

2 Mar 2026

ZYME

10-K: Zymeworks Shifts to Royalty Focus, Reports $81.1M Loss

Zymeworks Inc. reports a net loss of $81.1 million for 2025, alongside significant regulatory approvals for zanidatamab and a new $250 million royalty financing deal.

NASDAQ

5 Mar 2025

ZYME

Zymeworks INC

10-K: Zymeworks Reports 2024 Results, Highlights Progress in Oncology and Autoimmune Disease Pipeline

Zymeworks' 2024 10-K filing highlights the company's progress in developing biotherapeutics for cancer and autoimmune diseases, including the FDA approval of Ziihera and advancements in its wholly-owned pipeline.

NASDAQ

6 Mar 2024

ZYME

Zymeworks INC

10-K: Zymeworks Inc. Outlines Capital Stock Structure and Strategic Pipeline Progress in 10-K Filing

Zymeworks Inc.'s 10-K filing details its capital stock structure, ongoing clinical trials, and strategic partnerships, highlighting its focus on developing novel biotherapeutics.